XYL-3001
Pharmaceutical compound
From Wikipedia, the free encyclopedia
XYL-3001, formerly known as PSYLO-3001, is a non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders, generalized anxiety disorder, and social phobia (social anxiety disorder).[1][2][3] Its route of administration is unspecified.[1] The drug is being developed by Xylo Bio (previously Psylo).[1][2] As of January 2025, it is in the preclinical research stage of development.[1][2] XYL-3001's chemical structure does not yet appear to have been disclosed.[1]
Other namesXYL3001; PSYLO-3001; PSYLO3001; Psylo-3001
Routes of
administrationUnspecified[1]
administrationUnspecified[1]
| Clinical data | |
|---|---|
| Other names | XYL3001; PSYLO-3001; PSYLO3001; Psylo-3001 |
| Routes of administration | Unspecified[1] |
| Drug class | Non-hallucinogenic serotonin 5-HT2A receptor agonist |
